US Stock MarketDetailed Quotes

PALI Palisade Bio

Watchlist

4.6100
+0.0400+0.88%

Close Jun 10 16:00 ET

4.32MMarket Cap-196P/E (TTM)

Palisade Bio Stock Forum

Jaguar8

May 21 07:45

$Palisade Bio(PALI.US)$
NEWS
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Dusters

May 2 08:19

$Palisade Bio(PALI.US)$ NICE. PRIVATE PLACEMENT AT 6.50. Bullish. Big news coming!!

Jaguar8

May 2 07:32

$Palisade Bio(PALI.US)$
NEWS
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

upper

May 1 14:51

$Palisade Bio(PALI.US)$ dig a grave for the shorties

Stock Region

May 1 14:41

Medical Research Company Reveals Milestone Study Results For Ulcerative Colitis Treatment

The implications for Palisade Bio (Nasdaq: PALI) stock are significant.
Where innovation and advanced therapeutic modalities pave the way for new treatments, Palisade Bio stands out with its groundbreaking research in combating autoimmune, inflammatory, and fibrotic diseases. The company's latest achievement in this domain, the development of PALI-2108, marks a significant milestone in the quest for effectiv...

upper

May 1 13:51

$Palisade Bio(PALI.US)$ Af pump

Dusters

May 1 13:32

$Palisade Bio(PALI.US)$ short sellers dont want this to run, because if it doea. It will shoot up over 20. if you’re not scared to make money, slap the ask and trigger those short sellers stoplosses.

sriz

May 1 12:09

$Palisade Bio(PALI.US)$ damn even with news its not shooting up

Dusters

May 1 12:07

$Palisade Bio(PALI.US)$ We need 3x the current price. lets go!

Jaguar8

May 1 11:52

$Palisade Bio(PALI.US)$
NEWS
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
PALI-2108 demonstrates potent anti-inflammatory effects in the treatment of UC, with superior efficacy compared to apremilast.
The successful completion of the study indicates a promising next-generation therapeutic option for patients with inflammatory bowel disease.
The Phase...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall